lopinavir /ritonavir accord 200 mg/50 mg film-coated tablets
accord healthcare ireland ltd euro house, euro business park, little island cork, t45 k857, ireland - lopinavir, ritonavir - film-coated tablet - lopinavir 200 mg ritonavir 50 mg - antivirals for systemic use
paxlovid
pfizer europe ma eeig - nirmatrelvir, ritonavir - covid-19 virus infection - paxlovid is indicated for the treatment of coronavirus disease 2019 (covid-19) in adults who do not require supplemental oxygen and who are at increased risk for progressing to severe covid 19.
paxlovid (nirmatrelvir 150 mg film-coated tablets and ritonavir 100 mg film-coated tablets)
pfizer (malaysia) sdn. bhd. - nirmatrelvir; ritonavir -
paxlovid (nirmatrelvir 150 mg film-coated tablets and ritonavir 100 mg film-coated tablets)
pfizer (malaysia) sdn. bhd. - nirmatrelvir; ritonavir -
paxlovid
pfizer new zealand limited - nirmatrelvir 150mg; ; ; ; ritonavir 100mg - film coated tablet - active: nirmatrelvir 150mg excipient: colloidal silicon dioxide croscarmellose sodium lactose monohydrate microcrystalline cellulose opadry pink 05b140011 purified water sodium stearyl fumarate active: ritonavir 100mg - paxlovid is indicated for the treatment of coronavirus disease 2019 (covid- 19) in adults 18 years of age and older, who do not require initiation of supplemental oxygen due to covid-19 and are at increased risk of progression to hospitalisation or death.
atazor-r tablets film-coated
emcure pharmaceuticals ltd. - atazanavir sulphate, ritonavir - tablets film-coated - 300mg+ 100mg
norvir 100 mg tablets
abbvie biopharmaceuticals ltd, israel - ritonavir - film coated tablets - ritonavir 100 mg - ritonavir - ritonavir - is indicated alone or in combination with other antiretroviral agents for the treatment of patients with hiv infection when therapy is warranted based on clinical and/or immunological evidence of disease progression
ritonavir 100 mg film-coated tablet
accord healthcare ireland ltd. - ritonavir - film-coated tablet - 100 milligram(s) - protease inhibitors; ritonavir
aluvia 100/25 tablet
abbvie (pty) ltd - tablet - see ingredients - each tablet contains lopinavir 100,0 mg ritonavir 25,0 mg
paxlovid nirmatrelvir 150 mg tablet and ritonavir 100 mg tablet blister composite pack
pfizer australia pty ltd - ritonavir, quantity: 100 mg - tablet, film coated - excipient ingredients: macrogol 3350; macrogol 400; sodium stearylfumarate; titanium dioxide; calcium hydrogen phosphate; sorbitan monolaurate; copovidone; hyprolose; purified talc; polysorbate 80; hypromellose; colloidal anhydrous silica - paxlovid has provisional approval for the treatment of coronavirus disease 2019 (covid-19) in adults 18 years of age and older, who do not require initiation of supplemental oxygen due to covid-19 and are at increased risk of progression to hospitalisation or death (see section 5.1 pharmacodynamic properties, clinical trials).,the decision has been made on the basis of short term efficacy and safety data. continued approval of this indication depends on the efficacy and safety data from ongoing clinical trials and post-market assessment.